Tag Archives: Chief Executive Officer Dr

Kopin Corporation Announces Stock Repurchase Program

By Business Wirevia The Motley Fool

Filed under:

Kopin Corporation Announces Stock Repurchase Program

TAUNTON, Mass.–(BUSINESS WIRE)– Kopin Corporation (NAS: KOPN) announced today that its Board of Directors has authorized the repurchase of up to $30 million of the Company’s common stock.

Kopin intends to finance the repurchase program with available cash. The Company plans to buy shares in the open market or through privately negotiated transactions from time to time over the next 12 months, subject to market conditions and other factors and in compliance with applicable legal requirements. The plan does not obligate Kopin to acquire any particular amount of common stock, and can be suspended at any time at the Company’s sole discretion. Kopin has approximately 66.5 million shares of common stock outstanding. On March 15, 2013, the Company’s common stock closed at $3.58 per share.

“Our strong balance sheet provides the flexibility to implement this buyback plan judiciously to create further value for our shareholders,” said Kopin President and Chief Executive Officer Dr. John C.C. Fan. “With approximately $140 million in cash and equivalents as of February 23, 2013, and no long-term debt, Kopin has ample resources to carry out this program and aggressively pursue our long-term growth initiatives. We believe that our strategy to leverage our technology expertise to develop critical components and license reference systems for branded wearable computing products creates a compelling opportunity for investors.”

About Kopin

Kopin® (NAS: KOPN) is leading a new category of cloud computing with Golden-i, the Company’s hands-free, voice-activated technology platform for mobile computing and communications. With an intellectual property portfolio covering all of the required technologies for wearable computing — software, speech enhancement, display technology, low power circuits, optics, and ergonomics — Kopin is developing a platform that gives users complete communications mobility and full-color HD image quality. Golden-i is an award-winning system designed for a broad range of applications including industrial, medical, emergency response, consumer, professional, engineering, homeland security and military. Kopin’s proprietary technologies are protected by more than 200 global patents and patents pending. For more information, visit www.kopin.com.

Safe Harbor Statement

Statements in this news release about Kopin’s plan to repurchase up to $30 million in common stock over the next 12 months may be considered “forward-looking” statements under …read more
Source: FULL ARTICLE at DailyFinance

Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on March 19

By Business Wirevia The Motley Fool

Filed under:

Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on March 19

Presentation to be Webcast Live at 3:30 p.m. ET / 2:30 p.m. CT

BEDFORD, Mass.–(BUSINESS WIRE)– Anika Therapeutics, Inc. (NAS: ANIK) a leader in products for tissue protection, healing and repair, based on hyaluronic acid (“HA“) technology, today announced that Chief Executive Officer Dr. Charles Sherwood will be presenting at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 19, 2013 at 3:30 p.m. ET / 2:30 p.m. CT. The conference is being held at the Westin Michigan Avenue in Chicago.

An audio webcast of the presentation will be available live and may be accessed via the “Investor Relations” section of Anika’s website at www.anikatherapeutics.com. An archive of the presentation also will be available on the website.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products range from orthopedic/joint health solutions led by Orthovisc®, a treatment for osteoarthritis of the knee; to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika’s Italian subsidiary, Anika Therapeutics S.r.l, provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in areas such as advanced wound treatment and ear, nose and throat care. Its regenerative tissue technology advances Anika’s vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
President and CEO

KEYWORDS:   United States  North America  Illinois  Massachusetts

INDUSTRY KEYWORDS:

The article Anika Therapeutics to Present at the Canaccord Genuity Musculoskeletal Conference on March 19 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The …read more
Source: FULL ARTICLE at DailyFinance